Augustine Therapeutics has dosed the first patient in its Phase I clinical trial evaluating lead candidate AGT-100216, the first peripherally-restricted, selective cytosolic Histone DeACetylase 6 (HDAC6) inhibitor for the treatment of Charcot-Marie-Tooth disease (CMT), an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain, spinal cord, and the rest of the body.

Augustine is focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the HDAC6 enzyme.

The Phase I trial is a randomised, double-blind, placebo-controlled, first-in-human trial, designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of oral AGT-100216 in healthy adult volunteers. The trial is a combined two-part study evaluating single ascending and multiple ascending doses of AGT-100216.

Dr Gerhard Koenig, CEO of Augustine, said: “The initiation of our first clinical trial is a major milestone for Augustine. Decades of research have validated the therapeutic potential of HDAC6 as a target but efforts to drug it to date have been sub-optimal. Augustine is developing a new generation of HDAC6 inhibitors, like AGT-100216, with a unique mechanism of action shown to be selective, safe and effective in pre-clinical trials.

“Having recently raised €78 million ($85 million) in an oversubscribed Series A financing round, and with a strengthened management team, the company is entering a new stage of growth. We are well positioned to progress AGT-100216 through clinical development for CMT and to also advance our pipeline of next-generation HDAC6 inhibitors in significant cardio-metabolic and neurodegenerative diseases.”

Megan Thomas, Multimedia Editor, DDW